-+ 0.00%
-+ 0.00%
-+ 0.00%

The Zhitong Finance App learned that Novo Nordisk (NVO.US) announced on Monday that in a late-stage clinical trial, if the test children fully followed the treatment plan, the active ingredient in the major weight loss drug Wegovy, semaglutide (semaglutide), could cause 40.4% of obese children under 6 to 12 years old to no longer be classified as obese after 68 weeks.

Zhitongcaijing·09/07/2026 12:25:07
Listen to the news
The Zhitong Finance App learned that Novo Nordisk (NVO.US) announced on Monday that in a late-stage clinical trial, if the test children fully followed the treatment plan, the active ingredient in the major weight loss drug Wegovy, semaglutide (semaglutide), could cause 40.4% of obese children under 6 to 12 years old to no longer be classified as obese after 68 weeks.